The lethal phenotype of cancer: The molecular basis of death due to malignancy

CA Cancer Journal for Clinicians

Volumn 57, Issue 4, 2007, Pages 225-241

  Loberg, Robert D ^a   Bradley, Deborah A ^b   Tomlins, Scott A ^b   Chinnaiyan, Arul M ^a,c   Pienta, Kenneth J ^a,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c University of Michigan ^*

^d Internal Medicine and Urology

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATRASENTAN; BISPHOSPHONIC ACID DERIVATIVE; CYTOKINE; HEPARIN DERIVATIVE; RECOMBINANT THROMBOMODULIN; THROMBIN INHIBITOR; WARFARIN; ZOLEDRONIC ACID;

ANEMIA; BONE CANCER; BREAST CANCER; CACHEXIA; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DYSPNEA; GENE MUTATION; HUMAN; KIDNEY CANCER; LETHALITY; LUNG CANCER; METASTASIS; MICROENVIRONMENT; MOLECULAR CLONING; MOUTH CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; VENOUS THROMBOEMBOLISM; GENETICS; MOLECULAR BIOLOGY; MORTALITY; NEOPLASM; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS;

ANTINEOPLASTIC AGENTS; CACHEXIA; CYTOKINES; DYSPNEA; HUMANS; MOLECULAR BIOLOGY; NEOPLASM METASTASIS; NEOPLASMS; PHENOTYPE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS;

EID: 34548192060     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/canjclin.57.4.225     Document Type: Review

References (145)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Pienta KJ, Loberg R. The "emigration, migration, and immigration" of prostate cancer. Clin Prostate Cancer 2005;4:24-30.
3. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-458.
4. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-573.
5. Ewing J. Metastasis, in Ewing J. Neoplastics. 3rd ed. Philadelphia, PA: Saunders; 1928:77-89.
6. Radman M, Matic I, Taddei F. Evolution of evolvability. Ann NY Acad Sci 1999;870:146-155.
7. Greaves M. Cancer causation: the Darwinian downside of past success? Lancet Oncol 2002;3:244-251.
8. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-28.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
10. Nesse RM, Williams GC. Evolution and the origins of disease. Sci Am 1998;279:86-93.
11. Coffey DS. Similarities of prostate and breast cancer: Evolution, diet, and estrogens. Urology 2001;57:31-38.
12. Farinati F, Cardin R, Della Libera G, et al. The role of anti-oxidants in the chemoprevention of gastric cancer. Eur J Cancer Prev 1994;3(suppl):93-97.
13. Sugarbaker PH. Metastatic inefficiency: the scientific basis for resection of liver metastases from colorectal cancer. J Surg Oncol 1993;3(suppl):158-160.
14. Luzzi KJ, MacDonald IC, Schmidt EE, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998;153:865-873.
15. Glaves D, Huben RP, Weiss L. Haematogenous dissemination of cells from human renal adenocarcinomas. Br J Cancer 1988;57:32-35.
16. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-939.
17. Grego-Bessa J, Diez J, Timmerman L, de la Pompa JL. Notch and epithelial-mesenchyme transition in development and tumor progression: another turn of the screw. Cell Cycle 2004;3:718-721.
18. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-379.
19. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54.
20. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
21. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115:1503-1521.
22. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
23. Minn AJ, Kang Y, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005;115:44-55.
24. D'Arrigo A, Belluco C, Ambrosi A, et al. Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer 2005;115:256-262.
25. Budhu AS, Zipser B, Forgues M, et al. The molecular signature of metastases of human hepatocellular carcinoma. Oncology 2005;69(suppl):23-27.
26. Jones J, Otu H, Spentzos D, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005;11:5730-5739.
27. O'Donnell RK, Kupferman M, Wei SJ, et al. Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. Oncogene 2005;24:1244-1251.
28. Wang W, Wyckoff JB, Frohlich VC, et al. Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res 2002;62:6278-6288.
29. Pantel K, Woelfle U. Micrometastasis in breast cancer and other solid tumors. J Biol Regul Homeost Agents 2004;18:120-125.
30. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
31. Weigelt B, Hu Z, He X, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005;65:9155-9158.
32. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-209.
33. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-826.
34. Woelfle U, Cloos J, Sauter G, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 2003;63:5679-5684.
35. Cancer Bioinformatics, Comprehensive Cancer Center, University of Michigan. Cancer Profiling Database: ONCOMINE™. Available at: www.oncomine.org. Accessed March 12, 2007.
36. Chung CH, Bernard PS, Perou CM. Molecular portraits and the family tree of cancer. Nat Genet 2002;32(suppl):533-540.
37. Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004;101:9309-9314.
38. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Mining for regulatory programs in the cancer transcriptome. Nat Genet 2005;37:579-583.
39. Rhodes DR, Chinnaiyan AM. Integrative analysis of the cancer transcriptome. Nat Genet 2005;37(suppl):S31-S37.
40. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51.
41. Yang H, Crawford N, Lukes L, et al. Metastasis predictive signature profiles pre-exist in normal tissues. Clin Exp Metastasis 2005;22:593-603.
42. Hunter KW. Host genetics and tumour metastasis. Br J Cancer 2004;90:752-755.
43. Shen R, Ghosh D, Chinnaiyan AM. Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data. BMC Genomics 2004;5:94.
44. Li HR, Wang-Rodriguez J, Nair TM, et al. Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens. Cancer Res 2006;66:4079-4088.
45. Hoang CD, Guillaume TJ, Engel SC, et al. Analysis of paired primary lung and lymph node tumor cells: a model of metastatic potential by multiple genetic programs. Cancer Detect Prev 2005;29:509-517.
46. Niklaus AL, Pollard JW. Mining the mouse transcriptome of receptive endometrium reveals distinct molecular signatures for the luminal and glandular epithelium. Endocrinology 2006;147:3375-3390.
47. Folkman J. Toward an understanding of angiogenesis: search and discovery. Perspect Biol Med 1985;29:10-36.
48. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003;2:803-811.
49. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.
50. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
51. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
52. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4:221-233.
53. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005;23:8232-8241.
54. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005;10:169-180.
55. Kakonen SM, Mundy GR. Mechanisms of osteolytic metastases in breast carcinoma. Cancer 2003;97(suppl):834-839.
56. Cancer Bioinformatics, Comprehensive Cancer Center, University of Michigan. Molecular Concept Map. Available at: http://www.molecularconcepts.org/ main/review.jsp. Accessed March 12, 2007.
57. Willis RA. The Pathology of Tumours. 4th ed. London, UK: Butterworths; 1967.
58. Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979;189:496-502.
59. Berge T, Lundberg S. Cancer in Malmo 1958-1969. An autopsy study. Acta Pathol Microbiol Scand 1977;260(suppl):1-235.
60. Hassan I. eMedicine from WebMD. Lung, Metastases. Available at: http://www.emedicine.com/radio/topic404.htm. Accessed March 13, 2007.
61. Roudier MP, Vesselle H, True LD, et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003;20:171-180.
62. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-9216.
63. Pickren JW, Tsukada Y, Lane WW. Liver metastasis, in Weiss L, Gilbert HA (eds). Analysis of Autopsy Data. Boston, MA: GK Hall and Company; 1982:2-18.
64. Weiss L, Grundmann E, Torhorst J, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986;150:195-203.
65. Reed E, Zerbe CS, Brawley OW, et al. Analysis of autopsy evaluations of ovarian cancer patients treated at the National Cancer Institute, 1972-1988. Am J Clin Oncol 2000;23:107-116.
66. Lee YT, Tatter D. Carcinoma of the pancreas and periampullary structures. Pattern of metastasis at autopsy. Arch Pathol Lab Med 1984;108:584-587.
67. Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 1983;23:175-180.
68. Cox JD, Yesner RA. Causes of treatment failure and death in carcinoma of the lung. Yale J Biol Med 1981;54:201-207.
69. Cho SY, Choi HY. Causes of death and metastatic patterns in patients with mammary cancer. Ten-year autopsy study. Am J Clin Pathol 1980;73:232-234.
70. Viadana E, Au K-L. Patterns of metastases in adenocarcinomas of man. An autopsy study of 4,728 cases. J Med 1975;6:1-14.
71. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69:491-497.
72. Inagaki J, Rodriguez V, Bodey GP. Proceedings: Causes of death in cancer patients. Cancer 1974;33:568-573.
73. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005;6:401-410.
74. Dudgeon DJ, Kristjanson L, Sloan JA, et al. Dyspnea in cancer patients: prevalence and associated factors. J Pain Symptom Manage 2001;21:95-102.
75. Tisdale MJ. Molecular pathways leading to cancer cachexia. Physiology (Bethesda) 2005;20:340-348.
76. Argiles JM, Busquets S, Felipe A, Lopez-Soriano FJ. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol 2005;37:1084-1104.
77. Muscaritoli M, Bossola M, Aversa Z, et al. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 2006;42:31-41.
78. Capra S, Ferguson M, Ried K. Cancer: impact of nutrition intervention outcome - nutrition issues for patients. Nutrition 2001;17:769-772.
79. Evans WK, Nixon DW, Daly JM, et al. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung caner. J Clin Oncol 1987;5:113-124.
80. Ovesen L, Allingstrup L, Hannibal J, et al. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 1993;11:2043-2049.
81. Klein S, Kinney J, Jeejeebhoy K, et al. Nutrition support in clinical practice: review of published data and recommendations for future research directions. Summary of a conference sponsored by the National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition. Am J Clin Nutr 1997;66:683-706.
82. Pascual Lopez A, Roque i Figuls M, Urrutia Cuchi G, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004;27:360-369.
83. Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004;22:2469-2476.
84. Nagaya N, Kojima M, Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia. Intern Med 2006;45:127-134.
85. Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005;128:1187-1193.
86. Hamerman D. Molecular-based therapeutic approaches in treatment of anorexia of aging and cancer cachexia. J Gerontol A Biol Sci Med Sci 2002;57:M511-M518.
87. Boddaert MS, Gerritsen WR, Pinedo HM. On our way to targeted therapy for cachexia in cancer? Curr Opin Oncol 2006;18:335-340.
88. Fearon KC, Barber MD, Moses AG, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006;24:3401-3407.
89. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-2285.
90. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii-iv,xi-xiii,1-229.
91. Trousseau A. Phlegmasia alba dolens, in Clinique Medicale de L'Hotel Dieu de Paris. 2nd ed. Paris, France: Bailliere; 1865:695-739.
92. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575-579.
93. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-291.
94. Elamin EM, Glass M, Camporesi E. Pharmacological approaches to ameliorating catabolic conditions. Curr Opin Clin Nutr Metab Care 2006;9:449-454.
95. DeBoer MD, Marks DL. Cachexia: lessons from melanocortin antagonism. Trends Endocrinol Metab 2006;17:199-204.
96. Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006;4:48.
97. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006;2:619-626.
98. Wallner L, Dai J, Escara-Wilke J, et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 2006;66:3087-3095.
99. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850.
100. Svendsen E, Karwinski B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 1989;42:805-809.
101. Ogren M, Bergqvist D, Wahlander K, et al. Trousseau's syndrome - what is the evidence? A population-based autopsy study. Thromb Haemost 2006;95:541-545.
102. Mousa SA. Role of current and emerging antithrombotics in thrombosis and cancer. Drugs Today (Barc) 2006;42:331-350.
103. Deitcher SR. Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis 2003;16:21-31.
104. Lee AY. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res 2003;110:167-172.
105. Rak J, Milsom C, May L, et al. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006;32:54-70.
106. Hiller E. Cancer and thrombosis: managing the risks and approaches to thromboprophylaxis. Onkologie 2006;29:474-478.
107. Nakchbandi W, Muller H, Singer MV, et al. Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. Scand J Gastroenterol 2006;41:1095-1104.
108. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007;5:31-41.
109. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944-1948.
110. Fagnani D, Franchi R, Porta C, et al. Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis. Ann Oncol 2007;18:551-555.
111. Linenberger ML. Catheter-related thrombosis: risks, diagnosis, and management. J Natl Compr Canc Netw 2006;4:889-901.
112. Schwienhorst A. Direct thrombin inhibitors - a survey of recent developments. Cell Mol Life Sci 2006;63:2773-2791.
113. Yeh RW, Jang IK. Argatroban: update. Am Heart J 2006;151:1131-1138.
114. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
115. Mousa SA. Arixtra (fondaparinux sodium). Methods Mol Med 2004;93:239-246.
116. Eigenbrot C, Meng YG, Krishnamurthy R, et al. Structural insight into how an anti-idiotypic antibody against D3H44 (anti-tissue factor antibody) restores normal coagulation. J Mol Biol 2003;331:433-446.
117. Hirte H, Vergote IB, Jeffrey JR, et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 2006;102:300-308.
118. Lara PN Jr, Stadler WM, Longmate J, et al. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 2006;12:1556-1563.
119. Overall CM, Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006;94:941-946.
120. Berkenblit A, Matulonis UA, Kroener JF, et al. A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol 2005;99:50-57.
121. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004;10:39-49.
122. Leung-Toung R, Zhao Y, Li W, et al. Thiol proteases: inhibitors and potential therapeutic targets. Curr Med Chem 2006;13:547-581.
123. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506-520.
124. Iyer S, Wang ZG, Akhtari M, et al. Targeting TGFbeta signaling for cancer therapy. Cancer Biol Ther 2005;4:261-266.
125. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signaling inhibitors for cancer therapy. Nat Rev Drug Discov 2004;3:1011-1022.
126. Kumar S, Dare L, Vasko-Moser JA, et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 2007;40:122-131.
127. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006;12:6296s-6300s.
128. Santini D, Fratto ME, Vincenzi B, et al. Zoledronic acid in the management of metastatic bone disease. Expert Opin Biol Ther 2006;6:1333-1348.
129. Lin A, Ray ME. Targeted and systemic radiotherapy in the treatment of bone metastasis. Cancer Metastasis Rev 2006;25:669-675.
130. Bauman G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for the palliation of painful bone metastasis - a systemic review. Radiother Oncol 2005;75:258-270.
131. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109:3207-3213.
132. Close P, Neuprez A, Reginster JY. Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother 2006;7:1603-1615.
133. Lewiecki EM. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 2006;6:1041-1050.
134. Tonra JR, Hicklin DJ. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy. Immunol Invest 2007;36:3-23.
135. Baka S, Clamp AR, Jayson GC. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 2006;10:867-876.
136. Lierman E, Lahortiga I, Van Miegroet H, et al. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica 2007;92:27-34.
137. Herbst RS, Heymach JV, O'Reilly MS, et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 2007;16:239-249.
138. Cashen AF, Nervi B, DiPersio J. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Future Oncol 2007;3:19-27.
139. Loberg RD, Day LL, Harwood J, et al. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 2006;8:578-586.
140. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007;43:481-489.
141. Astsaturov I, Cohen RB, Harari PM. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 2006;6:691-710.
142. Ripamonti C. Management of dyspnea in advanced cancer patients. Support Care Cancer 1999;7:233-243.
143. Ripamonti C, Bruera E. Dyspnea: pathophysiology and assessment. J Pain Symptom Manage 1997;13:220-232.
144. Thomas JR, Von Gunten CF. Treatment of dyspnea in cancer patients. Oncology (Williston Park) 2002;16:745-750.
145. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest 1986;89:234-236.